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INTRODUCTION 
Influenza remains a major public health problem in many countries. Periodic epide- 
mics disrupt economic and social activities within entire communities, impose sudden 
large demands on available medical facilities, and can cause excess mortality, particularly 
in the elderly or those with certain chronic illnesses [5,7,21]. 
Vaccination can provide significant protection against infection and illness during 
natural epidemics, but this protection is usually considered to be of  limited duration, 
particularly due to the changes in antigenic specificity of  influenza virus surface glyco- 
proteins (hemagglutinin (HA) and neuraminidase (NA)) which continually occur [58]. 
This problem affects the two methods that exist for influenza vaccination. Inactivated 
(killed) vaccines must be constantly updated to include newer strains, which in any event 
often induce maximum antibody responses not to themselves but to previously prevalent 
strains, as expounded in the 'Doctrine of  Original Antigenic Sin' [48,62]. Live, attenuat- 
ed virus vaccines might be expected to produce a more long-lasting protection than inacti- 
vated vaccines on the assumption that they would mimic natural infection which, for 
unknown reasons, probably protects longer than inactivated vaccines [15]. However, 
live vaccines must be infectious, attenuated, induce protective immunity and be genetic- 
ally stable, a combination of properties that might not be obtained in a short space of 
time with each important new strain (antigenic variant) as it appears. 
The ability to recombine influenza viruses by mixed infections during which the 
segmented RNA genome can reassort [52] raised the prospect that once a suitable 
attenuated vaccine strain of  influenza A was prepared, this property could be transferred 
to a new strain with contemporary HA and NA antigens [8,35,37]. Provided only that 
these glycoproteins did not contribute significantly to other (non-antigen dependent) 
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vaccine-required properties, attenuated recombinants should be rapidly obtained in this 
way. 
This strategy has been adopted now, using several prospective attenuated strains as 
donors in recombinations with contemporary wild-type (wt)  viruses. The work with 
highly laboratory-passaged attenuated strains, such as A/PR/8/34 (H1N1)or  A/Okuda/ 
57 (H2N2), has been described elsewhere [10,16,39,47,57]. Although subjected to 
extensive clinical studies, and in some cases commercially dsitributed, these vaccines 
are not currently being used except for occasional special research investigations. A 
second approach to the use of recombinant live virus vaccines was that of  Chanoek and 
coworkers, who followed a suggestion by Mackenzie [37] that temperature-sensitive 
(ts)* variants might be attenuated. Methods were developed for introducing one or more 
single step lesions into influenza viruses and then transferring the ts genes to new wt 
strains by recombination. Although the two most widely studied ts donors (TS 1-E and 
TS l-A-2) had many desirable properties for live vaccine use, instability of  the pheno- 
typic ts marker (associated in at least one case with reversion to virulence) proved a major 
obstacle [60]. 
A third alternative in the preparation of recombinant live virus vaccines is the use of 
cold-adapted (ca) viruses as attenuated donor strains. This concept has been studied in 
the Soviet Union since at least 1965 [4] where in many years ca influenza viruses have 
been empirically selected for use in widespread vaccination activities. Because of the re- 
ported success in the Soviet Union with ca live vaccines, research in this area has been under- 
taken also in the United States, including investigation of methods for obtaining such vari- 
ants and testing their biological properties in vitro [30], in animal models [32] and in 
some preliminary human volunteer studies [9]. In both countries there has been active 
application of genetic recombination (reassortrnent) and of newly developed molecular 
techniques, to analyze the properties of  donor-attenuated ca viruses and their reeombi- 
nants as an aid to the development of  live, attenuated influenza vaccines. These recent 
advances are the subject of  this review. 
DONOR-ATTENUATED STRAINS 
Method o f  obtaining donor-attenuated strains 
In the U.S.S.R. and the U.S.A. a large number of  field strains of influenza A viruses 
of different subtypes have been adapted to growth at suboptimal temperatures (<30°C) 
as a potential method for attenuating the virus' virulence [ 1,4,30,31,34,54]. Only a small 
number of these strains, however, have been used in recombination experiments designed 
to transfer the cold-adaptation property to candidate vaccines for human use. In the 
U.S.S.R. these donor strains consist of  A/Leningrad/9/46(HINl) and A/Leningrad~134/ 
* ts is used to designate viruses exhibiting >10 s loglo reduction in infectious titer at non-permissive 
temperatures of >38°C compared to titer at permissive temperature of 33-34°C. 
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57(H2N2) [4], and in the U.S.A. most recombination studies have used A/Ann Arbor/ 
6/60(H2N2) as the ca donor parent. 
Prior to adaptation to growth at 25°C, the Leningrad viruses received 20 or more 
chick embryo (egg allantoic cavity) passages at 32°C. Subsequently they were passaged 
17-47  times in eggs at 25-26°C for 4 or 5 days. During the cold-adaptation procedure, 
it was twice necessary to passage the H2N2 virus at 31°C for 2 days to maintain viability 
and later passages were at 26°C for 4 days rather than 25°C for 5 days, with higher yield 
obtained [4]. Experience in the U.S.A., starting with viruses that had fewer egg passages 
at 32°C, was consistent that field strains of influenza did not normally contain ca mu- 
tants capable of replicating efficiently at 25°C. Accordingly, a procedure of stepwise 
adaptation to growth at lower temperatures was adopted. A field strain of H2N2 influen- 
za, A/Ann Arbor/6/60, was isolated in primary chicken kidney (CK) cells and then 
passaged 10 times in CK cells at 33°C and 10 times at 30°C. Although on initial passage 
at 30°C the virus yield was 2 -3  logs lower than at 33°C, after 10 passages at this tem- 
perature virus was selected that grew equally efficiently at 30°C as the original field 
strain had done at 33°C. This process of progressive adaptation was repeated by growing 
the mutant at 27°C for 10 passages and finally at 25°C for 10 passages (Table 1). It 
should be noted that this line of ca A/Ann Arbor/6/60 differs from that developed for 
evaluation in an animal model [30] in its lower number of CK passages, and absence 
of mouse lung passages, prior to adaptation to growth at 25°C. 
Biological  proper t i es  o f  d o n o r - a t t e n u a t e d  strains 
The ca A/Ann Arbor/6/60 mutant and the Leningrad ca mutants selected for high 
growth at temperatures below 30°C shared the property of restricted replication in 
embryonated eggs at the elevated temperature of 39--40°C (Table 2). Characterization 
of replication of the ca A/Ann Arbor/6/60 virus has been done not only in embryonated 
eggs, but also by plaque titration in primary CK cells. No detectable plaques are produced 
TABLE 1 
Isolation and passage history of cold-adapted influenza A/Ann Arbor/6/60 mutant used for preparing 
recombinant vaccine candidates 







30- 32 a 
Throat swab, incubate at 36°C in CK cells 
CK~ isolate, incubate at 36°C in CK cells 
Serial passages, incubate at 33°C in CK cells 
Serial passages, incubate at 30°C in CK cells 
Serial passages, incubate at 25°C in CK cells 
Serial plaque purification, at 25°C in CK cells 
Serial passage at 25°C in specific pathogen-free hens' eggs 
a Recombinants prior to AA-CR 22 were prepared from a stock passaged in standard hens' eggs. 
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TABLE 2 
Replication temperature markers of cold-adapted viruses used as parents in the preparation of recom- 
binant vaccine candidates 
Replication of cold-adapted parental virus 
in eggsa at (°C) haCK eellsb at (°C) 
25 28 33 39-40 25 33 39 
A/Leningrad[9/46(H1N1) 2.25 8.25 8.25 2.25 ND e ND ND 
A/Leningrad/134/57(H2N2) 4.75 8.25 8.25 2.25 ND ND ND 
A/Ann Arbor/6/60(H2N2) 7.50 ND 8.50 1.30 8.30 8.70 <3.0 
a EIDso (loglo) after 2-3 days at 33°C or 39°C and after 5 days at 25°C. 
b Plaque-forming units (log~o) after 3 -4  days at 25°C, 33°C or 390C, and after 5-7  days at 25°C. 
c Not done. 
at 39°C in contrast to the wild-type (wt) virus. Similar results are obtained in M a d i n -  
Darby canine kidney (MDCK) cell cultures (not  shown). The ca mutant ,  but  not  the wt  
A/Ann Arbor /6 /60  virus, also produces plaques in primary CK cells at 25°C, which 
provides a convenient mechanism for preparing ca recombinants,  as described below. 
Another  biological proper ty  analyzed for the ca A/Ann Arbor /6 /60 virus is its virulence 
in the ferret animal model  system. The wt  virus replicates to a higher t i ter  than its ca 
derivative and is isolated from lungs as well as turbinates (Table 3). Greater replication 
of  the w t  virus is accompanied by a febrile response and the product ion of  purulent 
rhinitis which are not  produced by infection with the ca mutant .  
Detection o f  genetic mutations in donor ca virus strains 
Most work has been directed towards determining the genetic basis for the ts pheno- 
type o f  the ca viruses. Traditionally,  determination o f  the gene possessing the condition- 
al rethal ts lesion in one mutant  microorganism has been determined by analyzing the 
ability o f  the mutant  to complement or recombine with other ts mutants  whose lesions 
TABLE 3 
Replication of wild-type and cold-adapted A/Ann Arbor/6/60 virus in ferrets a 
Time post- Infectivity titer b 
infection (h) Wild-type Mutant 
Turbinates Lungs Turbinates Lungs 
48 5.7 1.7 4.3 <1.0 
96 5.5 2.5 3.5 <1.0 
192 3.5 1.0 <1.0 <:1.0 
a Ferrets were infected intranasally with about 107.5 EIDso of virus. 
b Log~o EIDs0/ml of 20% tissue suspension. 
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have been previously defined. Because influenza viruses have a segmented genome, re- 
assortment o f  individual RNA segments can occur in mixed infections analogous to 
recombination, so that both recombination and complementation analyses o f  ts  lesions 
are possible. 
Each of  the ca Leningrad donor viruses has been examined by recombination analysis 
with a set of  six previously characterized fowl plague virus ts  mutants which have single- 
step ts  lesions in genes coding for their internal proteins [6 ,18-20,24,38] .  The A/ 
Leningrad/9/46 (H1N1) virus failed to recombine with fowl plague mutants possessing 
lesions in the P3 gene (RNA 1), the P1 gene (RNA 2) and the matrix protein gene sug- 
gesting the presence o f  mutations in these three genes in the ca  Leningrad strain (Table 
4). The ca  A/Leningrad/134/57(H2N2) virus, passaged at 25°C 17 times, failed to re- 
combine with fowl plague virus mutants having lesions in genes coding for P1, nucleo- 
protein, and matrix protein, also suggesting the existence of  mutations in three genes in 
this Leningrad ca  virus. After a further 30 passages at 25°C, the A/Leningrad/134/57 
ca virus additionally lost the ability to recombine with mutants possessing ts  lesions in 
the P1 gene (RNA 2) and the non-structural protein gene (RNA 8), so that in this more 
highly passaged virus a total of  five genes may contain ts  lesions. Due to possible incom- 
patibilities between certain gene constellations that can, for example, prevent the detec- 
tion o f  non-ts recombinants in some host systems [53],  definitive proof  of  the site o f  
ts  mutations (as with ca A/Ann Arbor/6/60) will require further detailed genetic and 
molecular analysis. 
The ca  A/Ann Arbor/6/60 mutant  has been analyzed by complementation analysis 
with a series of  single-step ts  mutants prepared by Murphy and colleagues [45,56] 
and by recombination analysis with single-step ts  mutants prepared by Sugiura and 
colleagues [59].  In the former case it was found that the ca mutant  failed to comple- 
TABLE 4 
Genetic analyses of cold-adapted (ca) Leningrad virus by recombination analysis with mutants of 
influenza A fowl plague virus (Dobson Weyhridge strain) having ts lesions in single genes 
FPV mutants 
Clone Protein with 
ts mutation 
Recombination frequency with ca virus 
A/Leningrad/9/46(H1N1) A/Leningrad/134/57(H2N2) 
25°C × 37 a 25°C X 17 a 25°C X 47 a 
29 b P3 < 0.01 < 0.01 <0.01 
131 b P1 < 0.01 22 <0.01 
166 b P2 1.7 8.0 2.0 
US1 e NP 1.2 < 0.01 <0.01 
3031 b M < 0.01 < 0.01 <0.01 
mN3 e NS 15 4.0 <0.01 
a Number of times passaged at 25°C. 
b Described in refs. 18-20, 24, 38. 
c Described in ref 1. These mutants were kindly supplied by Dr. B. Mahy. 
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ment  a virus R1 [54],  which has a defect in its P3 protein [49],  although complementa- 
tion did occur with ts  mutants from six other genetic groups. Recombination experiments 
comparing mutant  A/Ann Arbor/6/60 with Sugiura's ts  mutants  of  WSN virus, however, 
showed that the A/Ann Arbor/6/60 mutant  could recombine with the WSN mutant  
having a lesion in its P3 protein, but  could not  recombine with a WSN mutant  having a 
lesion in its P1 protein [13]. 
To resolve these contradictory findings, the genome composition was determined for 
several recombinants derived from the ca  A/Ann Arbor/6/60 virus. The surprising result 
was obtained (Table 5) that every gene of mutant  A/Ann Arbor/6/60 was present in one 
or more non-ts recombinant viruses. This indicated that possibly no single gene contained 
a ts lesion in the ca mutant ,  but rather a combination of two or more of its genes was 
necessary to obtain a ts  phenotype. The non-ts recombinant ($34) was found to contain 
a single w t  gene (P3, coded by RNA 1), showing that this gene of the mutant  A/Ann 
Arbor/6/60 was one of those involved in the group of  genes necessary for a ts  phenotype. 
Examination of recombinants having either ts  or non-ts phenotypes indicated that when. 
ever the A/Ann Arbor/6/60 P3 and matrix proteins segments were present in the virus, 
the virus was ts .  Thus, it is suggested that the ts  phenotype of mutant  A/Ann Arbor/6/60 
TABLE 5 
Properties of recombinants derived from mixed infections of A/Ann Arbor/6/60 mutant and WSN 
mutants or A/Ann Arbor/9/73 wild-type 
Recombinant clone Gene derivation b EOP (%) 
designation a P3 P1 P2 HA NP NA M NS p.f.u. 39°C/ 
(RNA 1) (RNA 2) (RNA 3) p.f.u. 33°C 
Ia s A A W W A A W A 12 
lu 2 A W W W W A W W 67 
Im s A W W W A A W A 25 
IIg I A W A A A A W A 25 
Vh s W W A W A W W W 50 
VIIbl W W W A W A A W 100 
VIIc I W A W W W A A A 25 
$32 O O A A A A A A 51 
$34 O A A A A A A A 19 
SI A O O O O A A A < 0.001 
S10 A A A A A A A O < 0.002 
M4 A O A O A O A A < 0.002 
No ts ÷ recombinants with A/Ann Arbor6/60 gene: 
4/9 3/9 4/9 4/9 
No ~ recombinants with A/Ann Arbor6/60 gene: 
3/3 1/3 2/3 1/3 
6/9 8/9 4/9 6/9 
2/3 2/3 3/3 2/3 
a,b A indicates the gene derived from the A/Ann Arbor/6/60 mutant; W indicates the gene derived 
from a WSN mutant; O indicates the gene derived from the A/Ann Arbor/9/73 wild-type virus. 
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results from synergism between these two viral proteins [13]. These findings do not 
exclude the possibilities that additional A/Ann Arbor/6/60 genes may affect the overall 
level of temperature sensitivity, or that the constellation of genes required for tempera- 
ture sensitivity may vary depending on the wt  parent used in recombination. 
The existence of mutations in all of  the genes of  ca A/Ann Arbor/6/60 virus has been 
detected by a combination of different biochemical techniques [11]. For example, com- 
parison of  RNA oligonucleotide maps indicated the existence of at least five detectable 
differences between the wt  and ca A/Ann Arbor/6/60 viruses in the approximately 10% 
of the genome that is analyzed by this procedure (Fig. 1). One spot difference occurred 
in each of the RNA segments RNA 1 (P3), 3 (P2) and 4 (HA), and two spot differences 
occurred in the nucleoprotein gene. 
The presence of mutations in genes coding for HA, NA, nucleoprotein, matrix protein 
and non-structural protein was determined by electrophoresis of heteroduplex RNAs 
prepared between wt  virion RNA and ca virus complementary RNA as described by Hay 
et al. [23], and existence of a mutation in RNA 2 (P1 gene) has been found by analysis 
of temperature sensitivity of virion transcriptase activity in recombinants of known 
genotype [26]. The multi-step nature of mutations in ca A[Ann Arbor/6/60 may explain 
the peculiarities of its reactions in complementation and recombination analyses. 
Biochemical studies have failed, however, to uncover any marker which might ex- 
plain the virus' temperature sensitivity of replication. All detectable polypeptides of the 
A/Ann Arbor/6/60 ca virus are synthesized with the same efficiency at the non-permissive 
temperature of 39°C as is observed with the wt  virus when tested in either CK or MDCK 
cell cultures, although an altered migration rate of polypeptide P2 has been observed 
[11]. The findings suggest that the mutation responsible for temperature sensitivity 
affects a late function in viral replication rather than any of the functions occurring 
prior to transcription of virion RNA into messenger RNAs and their translation into 
viral polypeptides. 
Infectiousness, reactogenicity and immunogenicity o f  donor-attenuated strains 
These properties have been examined for both of the ca Leningrad viruses by infec- 
tion of susceptible children. A total of 5164 children between the ages of I and 6 years 
old have been infected with the H2N2 A/Leningrad/134~57 ca virus. The studies were 
conducted in 1961-1964, years when some children would be expected to have hemag- 
glutinin-specific antibody to the H2N2 virus, which caused the Asian influenza pandemic 
in 1957, and periodic epidemics thereafter until 1968. Immunization of these healthy 
children involved intranasal administration with a sprayer of two doses (at about a 2 
week interval), each containing approximately 107 EIDso of the virus. Fever and clinical 
reactions were monitored for 5 days following immunization, and immunogenicity was 
evaluated by measuring the frequency of seroconversions detected by hemagglutination- 
inhibition (HI) tests. The percentage of children reported as showing febrile reactions 




Fig. 1. Oligonucleotide map of virion RNA of w t  and ca  A/Ann Arbor/6/60. Differences between the 
viruses are indicated by arrows. 
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exhibiting a ~>4-fold rise in titer of  HI antibodies. The A/Leningrad/9/46 (H1N1) ca virus 
was tested in 130 7 - 1 4  year old children in 1970, a time when the children would be 
expected to lack any immunity from prior infection because H1N1 viruses did not 
circulate between 1957 and 1977. Febrile reactions to the vaccine were reported in 0.7% 
of the children and a seroconversion rate of  approximately 70% was obtained. 
In the United States, the ca A/Ann Arbor/6/60 (H2N2) virus has never been tested 
in fully susceptible volunteers. Two studies, however, were done with volunteers known 
to possess low to moderate levels of  neutralizing antibody [13]. In the first study, 
6.4 X 104 TCIDso of virus was administered to volunteers with serum-neutralizing anti- 
body titers of  > 16, and no evidence for infection was obtained. In the second study, 
eight volunteers with serum-neutralizing antibody titers of  between 4 and 16 were inocul- 
ated with approximately 3 X l0 s TCIDso, and no illnesses were reported; virus was 
not recovered in the 9 days followed vaccination, but an antibody response was measured 
in seven of eight subjects 2 weeks after inoculation. 
RECOMBINANT ca ATTENUATED STRAINS 
M e t h o d  o f  prepara t ion  
Cold-adapted recombinant viruses deriving genes from the Leningrad ca strains have 
been obtained by infection of eggs with approximately 106-107 EIDso of a mixture 
containing one ca virus and one w t  strain. After mixed infection the eggs are incubated 
at 32°C for 10 h and subsequently two or three selective passages are performed in the 
presence of antiserum specific for the ca parent. These selective passages are done at 
either 25°C or 32°C. Final cloning of recombinants is done by triple-plaque purification 
in chick embryo kidney cell culture or, as a rule, by terminal dilution in chick embryos 
incubated at a temperature of  32°C. This procedure has reliably selected recombinants 
having surface antigens of  the w t  viruses and ca properties of  the Leningrad mutant 
parent used in the recombination. 
Recombinants of  the A/Ann Arbor/6/60 virus have been obtained by mixed infection 
of CK cells at 25°C with approximately 5 p.f.u./cell of  each of the two viruses. The 
infected cells are incubated at 25°C for several days until cytopathic effects are observed 
and the tissue culture fluid then used as a source o f  ca recombinants. Such recombinants 
are selected by two sequential passages in CK cells at 25°C in the presence of antiserum 
to the A/Ann Arbor/6/60 virus followed by two or three plaque purifications in CK 
ceils at 25°C in the absence of sera [33]. To increase the possibility of  obtaining recom- 
binants with different gene combinations, it is now customary to establish the mixed 
infection in 10 or 20 parallel CK cultures which are then maintained independently 
through all the steps of  the selection and cloning procedures [ 12]. 
Both in the U.S.S.R. and in the U.S.A. an attempt to increase the reproducibility of  
the recombination procedure, and to provide a better background for analyzing the 
effect of  recombination on the w t  virus, has been the cloning of the w t  virus prior to the 
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initiation of recombination. This cloning is done by passage of the wt  virus at 38-40°C 
in either eggs (U.S.S.R.) or bovine kidney or CK cells (U.S.A.) in order to assure that 
the parental virus is not ts. A t  least one plaque purification or terminal dilution passage 
in eggs is undertaken as part of this wt  virus cloning procedure. 
Biological properties o f  recombinant ca viruses 
The Leningrad ca viruses have been recombined with wt  influenza A (H1N1) or 
(H3N2) strains on eight occasions, and ca vaccine candidates recovered that have antigens 
of the contemporary wt  isolates (Table 6). A majority of the recombinants had a ts 
phenotype similar to that of their Leningrad parent, but in a few instances reduction or 
loss of ts phenotype occurred. 
In the U.S.A. ca A/Ann Arbor/6/60 has been recombined on nine occasions with wt  
influenza A (I-I3N2) strains and on four occasions with wt  influenza A (H1N1) strains 
[11,12] (also see Table 12). More than 40 of the ca recombinants have been analyzed 
and with a single exception retained a highly ts phenotype [12,26,33,36] (and unpublish- 
ed results). The exception, CR 13 clone 0 which was not ts [36], may be improperly 
cloned as it contains extra RNA segments when analyzed by gel electrophoresis (un- 
published observations). 
A/Ann Arbor/6/60 recombinant clones intended for use in human volunteer studies 
are also evaluated in susceptible ferrets infected, as a rule, with 107-10 s EIDso of virus 
(approximately 100-1000 median ferret infectious doses). Histopathological studies are 
consistent with a milder response by the ferrets to infection with ca recombinant than 
with wt  virus (Fig. 2). Other markers examined are the ability to replicate well only in 
the turbinates (but poorly in the lungs), to have low reactogenicity, and not to revert 
in ts or ca phenotypes [14,28]. When ferret inoculum is in the range of 107-°-108-° 
EIDso the viruses were, with rare exception, restricted to growth in turbinates, and 
genetically stable (Table 7). On a single occasion revertant virus was isolated from ferrets 
infected with CR18 clone 7. Ferrets infected with CR31 clone 3, however, have consist- 
ently had virus isolated from lungs, and this virus was not is. The non-ts reisolate has 
been phenotypically stable on subsequent ferret passage, but does not cause disease in 
the animals, indicating that the ts phenotype can alter independently of attenuation 
in this animal model. The relationship of genetic composition to biological properties of 
the ca recombinants is discussed below. 
Infectiousness, reactogenicity and immunogenicity o f  cold-adapted recombinant viruses 
Standardized procedures for safety and immunogenicity (phase 1) tests of ca recom- 
binants derived from the A/Ann Arbor/6/60 mutant have been developed that are cur- 
rently followed by different clinical investigators in the U.S.A. This is done to provide 
uniform data on clinical reactogenicity, as well as to provide specimens for laboratory 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fg. 2. Histopathology of nasal turbinates in ferrets infected with wild-type (wt)  and cold-adapted 
(ca) recombinant influenza virus. A) Uninfected ferret. B) Ferret infected with wt  A/Victoria/3/75. 
At 4 days post-infection there is purulent rhinitis evidenced by the existence of an exudate of  inflam- 
matory cells, squamous metaplasia, and oedema of the connective tissue. C) Ferret infected with 
AA-CR19 clone 0 cold-adapted recombinant of A/Victoria/3/75. At 4 days post-infection localized 
rhinitis is observed with mild squamous metaplasia, but no purulent exudate. 
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TABLE 7 
Replication in ferrets 
A/Ann Arbor/6/60 a 
of cold-adapted influenza viruses derived by recombination with cold-adapted 
Recombinant Infecting Duration of virus replication Reversion Reacto- 
dose (days) genicity 
Turbinates Lungs 
AA-CR 6 clone 0 7.5 b 3 <2 c - - 
AA-CR 18 clone 7 7.5 8 <2 Non-ca, non-ts virus d 
at 4 days only 
AA-CR 19 done 0 7.7 4 <2 - d 
AA-CR 22 clone 1 7.5 4 <2 - - 
AA-CR 29 clone 2 7.7 5 <2 - - 
AA-CR 31 clone 3 8.0 3 3 Stable non-ts virus _d 
recovered in lungs 
AA-CR 31 clone 10 7.8 3 <2 - - 
AA-CR 33 clone 1 7.5 3 <2 - - 
AA-CR 35 clone 2 7.5 4 <2 - - 
a All wild-type parents of ca viruses replicated in ferret lungs and produced fever associated with 
purulent rhinitis. 
b Log 1° EIDso. 
c < l  log 1° EIDsn of virus present in 20% lung suspensions prepared from animals sacrificed 48 h 
post-infection. 
d Short-lived low-grade fever and histopathological evidence of patchy or diffuse purulent rhinitis 
observed in some ferrets separately infected with > IO~PEIDso . 
Expanded safety studies (phase 2) as well as studies of protective efficacy by artificial 
challenge or natural exposure in field trials (phase 3), are also undertaken. Additional 
studies have been described by investigators outside the U.S.A. for a few c a  recombinants. 
A summary of clinical studies performed with the recombinants is given in Table 9. 
Recombinants with H3N2 antigens, administered in phase 1 studies by nose drops at 
doses of 106.s-107.s TCIDso or greater, have infected about 75-100% of vaccinees 
as judged by virus isolation and serum HI antibody response [14,25,40,42] (Table 10). 
In these phase 1 trials usually no more than a single participant (about 10% of infected 
persons) has experienced more than a mild upper respiratory illness. Febrile or systemic 
symptoms in those few individuals who experienced them were transient and also not  
severe. In one trial, however, when undiluted AA-CR 18 virus containing 108.s TCIDso 
of virus was administered, one-third of the volunteers experienced some febrile or syste- 
mic reactions [42]. Less pronounced symptoms resulted when a lower vaccine dose 
was used. Other evidence for possible dose response of reactions was the report that a 
high dose of AA-CR 22 vaccine was associated with transient afebrile systemic reactions 
[40],  although these have not been seen with a smaller inoculum (R.B. Couch and 
T. Cates, unpublished results). These results with H3N2 c a  recombinants of A/Ann 
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TABLE 8 
Protocol for phase 1 (safety) testing of live vaccine in healthy young adults in the U.S.A. 
A. General procedure 
1. Pre-bleed potential vaccine participants. 
2. Test pre-study serum by HI, neutralization, or enzyme-linked immunosorbent (ELISA) assay, 
to identify volunteers who have maximum susceptibility to the vaccine virus. 
3. Quarantine all selected volunteers in restricted access area for 2-3 days to monitor for any 
developing illness. 
4. Under blind conditions, administer by drops vaccine or placebo (0.5 ml/nostril) to supine 
volunteers. Approximately 3/4 of participants receive vaccine, the remainder placebo. 
5. Monitor febrile, systemic and respiratory reactions and collect daily nasal wash specimens. 
6. After 2 weeks collect final serum specimen. Volunteers depart from restricted access area. 
B. Laboratory tests on specimens collected 
1. Inoculation of tube cultures of monkey kidney (MK) or Madin-Darby canine kidney (MDCK) 
cells at the permissive temperature of 34°C with dilutions of nasal wash specimens to titrate 
post-inoculation replication of virus, and verify cessation of virus shedding. Additional virus 
isolation studies are undertaken to diagnose possible non-influenza infections in case of illness 
in participants. 
2. Inoculation of tube cultures of MK or MDCK cells at the non-permissive temperature of 39°C 
with a low dilution of nasal wash specimens to detect possible revertant (non-ts) virus. 
3. Titration of virus isolates in primary chicken kidney cells at 25°C, 33°C and 39~C to examine 
stability o f  ca and  ts  markers. 
4. Titration of pre- and post-inoculation sera specimens by HI, and in some cases by neutraliza- 
tion and ELISA procedures, to detect and quantitate humeral antibody responses. 
5. In some cases titration of nasal wash specimens by neutralization and ELISA procedures to 
quantitate local antibody responses. 
Arbor /6 /60  therefore suggest that, when given at doses o f  about 107-+0.5 TCIDso, the 
viruses are infectious and immunogenic for selected, serologically susceptible, young 
adult volunteers, but  that  undiluted vaccines containing l0  s or greater TCIDso may 
exhibit undesirable, albeit short-lived, reactions. 
Open studies, in which participants are enrolled without  prescreening o f  their serolo- 
gic status, have been done for three H3N2 recombinants o f  ca A/Ann Arbor/6/60.  Daven- 
port  and collaborators [14,25] administered, by  nasal spray rather than drops, 106.s 
EIDso of  AA-CR6 to 25 healthy young adult volunteers, and compared doses of  10 s.s ,  
106.s and 107.s EIDso o f  AA-CR19 administered by  nasal spray to groups o f  approxima- 
tely 40 young adults. No significant clinical reactions were observed in any study, al. 
though the majori ty o f  the participants possessed some pre-existing ant ibody that might 
have conferred protect ion against illness induced by the vaccine. In the study with 
106"s EIDso o f  AA-CR6 vaccine, 15/19 (79%) o f  subjects with pre-existing HI ant ibody 
titers o f  < 6 4  exhibited a 4.fold ant ibody response. The study with AA-CR19 demon- 
strated 4-fold or greater ant ibody responses in 10/28 (36%), 15/26 (58%) and 13/18 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Infectiousness, immunogerdcity and reactogenicity of cold-adapted H3N2 A/Ann Arbor recombinant 
vaccines in phase 1 studies with young adult volunteers 
H3N2 Dose (loglo No. of No. (%) No. (%) infected with Refer- 
recombinants TCIDso) volunteers infected a HI Febrile or ence 
response systemic illness 
CR 18 clone 7 7.5 10 8 (80) 6 (75) 1 (13) 50 
8.5 12 12 (100) 11 (92) 4 (33) 50 
CR 19 clone 0 6.3 14 13 (93) 13 (93) 0 (0) 64 
7.5 13 12 (92) 10(83) 1 (8) 50 
CR 22 clone 1 6.8 9 9 (100) 9 (89) 1 (11) 64 
CR 29 clone 2 7.5 24 18 (75) 16 (89) 0 (0) 61 
CR 31 clone 3 7.7 12 12 (100) 7 (58) 0 (0) 61 
CR 31 clone 10 7.7 17 13 (76) 10 (77) 1 (8) 61 
HIN1 
recombinant 
CR 35 clone 2 7.5 25 24 (96) 11(46) b 0 (0) 53 
a Determined by virus isolation and antibody response. 
b Increased to 100% by use ofimmunoassay to detect serum IgG and IgM antibody responses. 
106"s and 107.s EIDso o f  virus, respectively. These results suggest that  doses o f  about  
106.s-107-s  EIDso o f  virus infect the majori ty o f  susceptible volunteers when given 
by spray. Studies are now planned to determine the median human infectious dose o f  
cold-adapted A/Ann Arbor /6 /60  recombinant vaccines in volunteers with low pre- 
existing ant ibody,  when vaccine is administered by  nasal drops (B. Murphy, personal 
communication).  
One open-field trial has been undertaken with AA-CR 29 clone 2 recombinant,  in 
which groups of  more than 200 college students received vaccine or placebo under 
blind conditions. No differences in respiratory illness rates reported by  the students 
(21-29%)  were seen between the groups within the week following vaccination (R. 
Couch and T. Cates, personal communication).  Serologic responses and protect ion 
against natural infection are still under evaluation. 
Cold-adapted H1N1 recombinants have also been evaluated in human volunteer 
tests. Phase 1 clinical studies using similar protocols to those developed with H3N2 
candidate vaccines were undertaken in the U.S.A. with a ca recombinant,  AA-CR-35, 
which derives its HA and NA antigens from an A / U S S R / 9 0 / 7 7 ( H 1 N 1 ) - l i k e  w t  virus 
strain [44].  All  o f  24 selected serologically susceptible volunteers were infected when 
a virus dose o f  107-s TCIDso was administered (Table 10). Maximum detect ion o f  in- 
fection required the use o f  an enzyme immunoassay [46] to measure serum ant ibody 
responses, because only 45% of  the participants responded to vaccination with a detec- 
table serum HI ant ibody response. Similarly to the H3N2 ca recombinants,  AA-CR 35 
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did not cause significant clinical reactions when given at doses of  107,s TCIDso or less. 
Comparable results were obtained with an additional recombinant (AA-CR33)of A/ 
USSR/90/77(H1N1)-like virus evaluated in Europe in young volunteers [51 ],  and with a 
recombinant independently prepared in Europe from the A/Ann Arbor/6/60 ca  parent 
[51,61]. 
Clinical studies in the U.S.A. of  the AA-CR35 H1N1 ca recombinant in healthy young 
adults include a phase 2 study involving about 100 persons, and an open field trial in 
which about 700 college students were vaccinated. In these larger studies, no significant 
reactions were observed compared to the placebo groups, but the vaccine immunogenicity, 
as judged by conventional HI tests, was only about 50-60% in serologically susceptible 
vaccinees (R. Couch and T. Cates, personal communication). This does not necessarily 
indicate low infectivity of the ca  recombinant, because natural infection similarly was 
associated with relatively poor antibody response in young adults during 1977 and 1978, 
when measured with conventional HI tests [22]. 
Because of observations of low reactogenicity in young adults, AA-CR35 vaccine was 
considered safe for testing in small numbers of  young children of  13-44 months old 
[29]. When a dose of  106.s TCIDso was administered to 11 children, eight (73%) were 
infected, all of  these shedding virus (for up to 13 days) and demonstrating serum HI 
antibody response. No febrile or systemic reactions were observed (Dr. P. Wright, per- 
sonal communication), and all virus isolates retained their t s  phenotype. 
Attempts to demonstrate protective efficacy of the ca  recombinants have been under- 
taken by R. Couch and T. Cares (Personal communication), including the above.mention- 
ed two open field trials, and studies where a small number of vaccinated volunteers are 
challenged with w t  virus under conditions similar to those used for the initial vaccination. 
To obtain maximum sensitivity in determining vaccine efficacy in the prevention of 
influenza illness, laboratory diagnosis of  viral infection is undertaken to verify that any 
illnesses are caused by influenza virus, and placebo groups are included. A total of  25 
volunteers vaccinated 1-3 months previously with ca  H3N2 or H1N1 recombinants 
have been challenged with w t  virus without any evidence of illness, whereas 37 controls 
experienced 50-68% illness rates (Table 11). Results of open field trials are still being 
evaluated. 
Preliminary clinical evaluations in the U.S.S.R. of  the ca  viruses derived by recombina- 
tion with the Leningrad c a  parental strains are done by immunizing healthy children or 
young adults, 17-25 years old, residents in communes. Pre-vaccine sera are collected and 
tested to identify vaccinees who have serum HI antibody titers of ~<8 to the vaccine 
strains. Some volunteers are also shown to lack detectable antineuraminidase antibody. 
The protocols are similar to those described above for evaluation of donor Leningrad ca  
strains. 
Results indicate that in most instances greater than two-thirds of the serologically 
susceptible participants (i.e. whose pre-vaccine serum HI titer is ~<8) were infected as 
judged by serum HI antibody response measurement (Table 6). Recombinants obtained 










































































































































































































































































































































































































































































































this may be attributable to the fact that the wt  A/Victoria/3/75 parent used in the re- 
combination experiments in the Soviet Union had undergone a spontaneous mutation 
during laboratory passage, and in contrast to the A]Victoria]3/75 wt  used in the U.S.A. 
had only moderate reactogeriicity and immunogenicity [50]. The poor immunogenicity 
suggested by the results for the recombinant clone H29 derived from A/Leningrad/538/ 
74 might be solely due to the small numbers tested. 
For the H1N1 recombinant clones neuraminidase antibody responses following vac- 
cination were also measured, to provide an additional indicator of  immunogenicity. In 
initially seronegative participants, neuraminidase antibody response was detected for 
37%, 24% and 15%, respectively, with clones H32/5, H25/17 and H25/5. All of the tested 
vaccines were highly attenuated, and clone H32/5 which had the highest overall immu- 
nogenicity was therefore selected for use in vaccine manufacture. 
Clones H47/7/2 and H47/25/1 which were attenuated by recombination between 
A/Bangkok/1/79(H3N2) or A/Leningrad/322/79(H1N1) wt  strains respectively and 
the 47-times, 25°C-passaged A/Leningrad/134/57(H2N2) ca mutant are presently being 
evaluated in 7 - 1 4  year old children, with preliminary results indicating a reactogenicity 
and high immunogenicity (M.R. Zykov, personal communication). 
Studies of protective efficacy by the ca Leningrad recombinants are not done by 
means of artificial challenge of volunteers immunized with vaccine or placebo, but by 
monitoring reported illness rates among vaccinated and non-vaccinated groups during 
the winter season. Under these circumstances, when laboratory diagnosis of  infection 
is not done, vaccine efficacy in reducing acute respiratory disease is dependent on the 
proportion of influenza to non-influenza infections in the communities studied (Uy.G. 
Ivannikov, personal communication). 
Ef fec t  o f  genome composition on properties o f  ca recombinant live-vaccine candidates 
Genome analyses of ca viruses derived by recombination with ca A/Ann Arbor/6/60 
at 25°C have revealed them to have a highly restricted composition. Of 40 clones examin- 
ed, 24 (61%) possessed only the HA and NA of wt  virus, but all other genes from the ca 
A/Ann Arbor/6/60 parent (Table 12) [11,12]. The remaining viruses always contained 
P2, P3 and nucleoprotein genes from the Ann Arbor ca parent, but a single one of the P1, 
matrix protein or non-structural protein genes from the wt  parent. Several recombinants 
with wt  P1 or non-structural proteins were recovered, but have not been found to differ 
markedly in any biological property from recombinants with all non-HA- and non-NA 
genes derived from the ca A/Ann Arbor/6/60 parent (Table 7) [12,26,27]. However, 
relative temperature sensitivity of A/Ann Arbor/6/60 recombinants can apparently vary 
somewhat, independently of gene combinations [43]. 
Only a single recombinant derived at 25°C was determined to have a wt  matrix pro- 
tein. As described above (Table 7), this recombinant (AA-CR 31 clone 3) exhibited 
instability of its ts phenotype in ferrets, supporting the view from results with recombi- 
nants derived at temperatures other than 25°C that matrix protein was involved in the 
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TABLE 12 
Gene composition of cold-adapted Ann Arbor viruses derived by recombination at 25°C 
Recombinants  HA NA Derivation of  genes a 
Expt.  Wild-type parent Clone P3 PI  P2 NP M NS 
(RNA 1) b (RNA 2) b (RNA 3) b 
AA-CR 6 A/Queensland/6/72 (H 3N 2) 0 W W A A A A A A 
AA-CR 12 A/Ann Arbor /9 /73(H3N2)  0 W W A A A A A A 
AA-CR 13 A/Dunedin14]73(H3N2) 5 W W A W A A A A 
9 W W A W A A A A 
AA-CR 18 AlScotland1840174(H3N2) O W W A A A A A W 
4 W A A A A A A W 
5 W A A A A A A W 
6 W W A A A A A W 
7 W W A A A A A W 
AA-CR 19 A/Victoria/3/75 {H3N 2) 0 W W A W A A A A 
AA-CR 22 A/Victoria/3/75 (H 3N 2) 1 W W A W A A A A 
17 W A A A A A A A 
AA-CR 29 A/Alaska/6/77 (H3N2) c 2 W W A A A A A A 
17 W W A A A A A A 
AA-CR 31 A/Alaska/6/77 (H3N2) c 2 W W A A A A A A 
3 W W A A A A W A 
4 W A A A A A A A 
10 W W A A A A A W 
12 W W A A A A A W 
13 W W A A A A A A 
16 W A A A A A A A 
17 W A A A A A A A 
19 W W A A A A A A 
20 W W A A A A A A 
AA-CR 33 (A/USSR/90/77(H1N 1) 1 W W A A A A A A 
2 W W A A A A A A 
AA-CR 35 A/H0ng Kong/123/77(H1N 1) c 2 W W A A A A A A 
AA-CR 36 A/Hong Kong /123 /77 (HlN1)  c 1 W W A A A A A A 
2 W W A A A A A A 
3 W W A A A A A A 
4 W A A A A A A A 
5 W W A A A A A A 
7 W W A A A A A A 
9 W W A A A A A A 
10 W W A A A A A A 
AA-CR 37 A/California] 1 O/78 (H 1N I ) 1 W W A A A A A A 
AA-CR 44 A/Beijing/2/79 (H3N2) c 6 W W A A A A A A 
11 W W A A A A A W 
16 W W A A A A A A 
20 A W A A A A A A 
a W indicates gene derived from wild-type parent. A indicates gene derived from 
b For reference conditions of electrophoresis without urea at 38°C [26]. 
c Adapted to growth in primary bovine kidney cells and cloned at 39°C in these 
mutant parent. 
ceils. 
expression of the A/Ann Arbor/6/6O ts phenotype. AA-CR 31 clone 3 did not exhibit 
unusual properties in a human volunteer study, however, and non-ts revertants were not 
detected amongst isolates recovered from the vaccinees [41]. 
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Occasionally viruses exhibiting partial reversion in either the ts or the ca phenotype 
(but not both phenotypic markers) have been identified as a small proportion of virus 
isolated from human volunteers or hamsters infected with Ann Arbor ca recombinants 
[42,55]. There has not yet been an examination of genetic changes or changes in human 
virulence, that might be exhibited by such partial revertants. 
The two ca recombinants used in the U.S.S.R. as live vaccines in public immunization 
programs in recent years, i.e. the H17 clone of A / L e n i n g r a d ] 8 2 1 7 6 ( H 3 N 2 ) ,  and the 32•5 
clone of  A/Khabarovsk[ 1[77(H 1N1), both contain only the HA and NA of their respec- 
tive w t  parent, but all six other genes derived from the A[Len ingrad[134157  (H2N2) 
ca parent [17] (Table 13). Recombinant clones H47/7/2 and H47/25/1 which were 
recently prepared using the 47-times, 25°C-passaged A [ L e n i n g r a d [ 1 3 4 / 5 7 ( H 2 N 2 )  parent 
similarly derived only their HA and NA genes from their w t  parents. Two other recom- 
binants, H/ l /4  and H/4[1 contained at least all seven genes other than the M protein 
from that w t  parent and were non-ts or partially ts respectively. The matrix protein gene 
in recombinant H/ l /4  could not be identified by the procedure used as it appeared to 
have undergone a spontaneous mutation during recombination and was not identical 
to the matrix protein in either parent. Results of genome analysis suggest that the matrix 
protein is probably not required for the ca phenotype of either A [ L e n i n g r a d / 1 3 4 / 5 7  or 
A[Leningrad[9146  ca donors, but is involved in the ts phenotype of these viruses. Com- 
parison of genotype with results of  clinical testing [17] (Tables 6 and 13) suggests that 
even those recombinants possessing only a single gene (M) from the ca parent were 
attenuated. Evaluation of genetic stability of recombinants during replication in human 
volunteer studies has been done for the H17 clone which contains all non-HA, non-NA 
genes from its ca parent. Eight isolates were obtained from vaccinees shedding virus and 
all retained the ts  phenotype, although the difference in titers at 40°C and 32°C for the 
isolates was 1 -2  loglo less than in the original vaccine. 
SUMMARY AND CONCLUSIONS 
In the Soviet Union and the United States ca variants of influenza A virus have been 
selected by multiple passage at temperatures suboptimal for replication of w t  virus. These 
ca variants replicate efficiently at 25°C or 28°C but are highly temperature.sensitive 
and unlike many w t  influenza A viruses will not replicate at 39-40°C.  
The ca mutant most widely used for preparing experimental vaccine strains in the 
U.S.A. is Ann Arbor/6/60 (H2N2), but due to a lack of serologically susceptible adult 
volunteers this variant has itself been only partially characterized for clinical and immu- 
nological response in man. However, a series of  recombinants deriving five or six of the 
non-HA, non-NA genes from the A[Ann Arbor/6/60 mutant, but HA, NA and sometimes 
one other, genes from w t  H3N2 or H1N1 strains have been tested in serologically suscep- 
tible human volunteers. When given by nose drop or spray at doses of about 10 ~ TCIDso 
or EIDso the viruses are highly attenuated. H3N2 recombinants are highly immunogenic, 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































when traditional assays for antibody response are used. Preliminary studies of protective 
efficacy using artificial challenges have been undertaken with encouraging results in small 
numbers of volunteers. 
Genetic and biochemical analysis has identified the existence of mutations in all 
eight genes of the ca A/Ann Arbor/6/60 virus, and those coding for the polymerase- 
associated proteins P1, P2 and P3, as well as the matrix protein have been implicated in 
some way with genetic or phenotypic in vitro markers, although the relevance to attenua- 
tion of any mutation detected by these means is unclear. Occasional partial revertants in 
ca or t s  phenotype have been shed by persons or animals infected with Ann Arbor-ca 
recombinants. Further studies are necessary to determine whether reversion of ca  or ts  
phenotypes is associated with increased virulence. Production of reproducible ca  recom- 
binants has probably been facilitated by their ability to produce plaques at 25°C which 
provides a positive selection mechanism. Techniques used consistently identify with 
high frequency recombinants possessing all non-HA, non-NA genes from their ca  A/Ann 
Arbor/6/60 parent. 
In the U.S.S.R. many findings are analogous to those in the U.S.A. The camutant most 
widely used for preparing vaccine strains, A/Leningrad/134/57, is also an H2N2 virus 
similar to A/Ann Arbor/6/60, although another ca  parent, A/Leningrad/9/46(H1N1), 
is sometimes used. Both viruses have been tested for their infectiousness, immunogenicity 
and reactogenicity by administration of 10 7 infectious units with a nasal spray to young 
children, and were reported to be attenuated and immunogenic. A series of recombinants 
prepared with these ca  parents and diverse w t  parents usually shared the important 
biological properties of the ca  parent, and the recombinants with properties most suitable 
for vaccine use possess all non-HA, non-NA genes of their ca parent. 
Genetic analysis indicates the existence of mutations in several genes of the Leningrad 
ca parents and implicates the matrix protein as containing a mutation necessary for 
temperature sensitivity. Revertant viruses have not yet been identified as being shed by 
vaccinated persons in the small number of instances this has been evaluated. Studies of 
protective efficacy by artificial challenge of vaccinated volunteers with virulent w t  virus 
are not possible in the Soviet Union, and analysis of vaccine efficacy is dependent on 
epidemiological observations of large population groups during periods of natural virus 
circulation. 
The common viewpoint is held by the authors that the identification of multiple 
mutations in ca parent strains following their selection in the laboratory, and the ability 
to transfer most or all of these genes to contemporary w t  strains by recombination 
(reassortment), facilitates the regular production of ca recombinants with reproducible 
biological properties and minimal chances of reverting to virulence, even though the 
actual genetic basis for attenuation is unknown, in common with other live virus vaccines. 
A possible effect of HA and NA genes from the w t  parent or the recombinants is not 
totally excluded, however. Studies of the relative efficacy of live attenuated vaccines, 
compared to inactivated vaccines, in populations with different immunological back- 
grounds and when exposed to different w t  virus strains have yet to be done. Continued 
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development, evaluation, and comparison of  live and inactivated influenza vaccines must 
continue as one approach to improving influenza prophylaxis, and at the present time c a  
influenza viruses are highly useful in preparing live vaccines for this purpose. 
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